Search results
Jun 18, 2024 · Breast Cancer Therapeutics Global Strategic Research Report 2024: A $90+ Billion Market by 2030 Featuring AstraZeneca, Celgene, Eisai, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, and Teva...
- Research And Markets
3 days ago · Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalData.
Jul 3, 2024 · The latest collaborator to join Open Targets is Celgene, a global biopharmaceutical company with expertise in the discovery, development and commercialisation of innovative therapies for patients with cancer, immune-inflammatory and other unmet medical needs, which will enhance the offerings of the current collaborators GSK, Biogen ...
4 days ago · The multi-year research and development collaboration with Prothena sees Celgene pay $100 million upfront, and also make a $50 million equity investment in the firm, with potential licence...
3 days ago · Celgene is to file its potential multiple sclerosis blockbuster ozanimod by the end of the year following phase 3 results showing it outperformed established injectable Avonex. Ozanimod was the...
Jun 25, 2024 · Celgene has raised a total funding of $45M over 3 rounds from 13 investors. Investors include Versant Ventures, BB Biotech and 11 others. Their latest funding round was of $4.1M on Feb 10, 2018 .
Jul 9, 2024 · Celgene Corp. has patented sphingosine 1-phosphate S1P5 receptor (EDG8) modulators reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis.
